Ramatroban

Ramatroban

Systematic (IUPAC) name
3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
Clinical data
Legal status	℞ (Prescription only)
Routes of administration	Oral
Identifiers
CAS Number	116649-85-5
ATC code	None
PubChem	CID 123879
IUPHAR/BPS	1910
ChemSpider	110413
UNII	P1ALI72U6C
ChEMBL	CHEMBL361812
Chemical data
Formula	C21H21FN2O4S
Molar mass	416.46 g/mol
SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
InChI InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N

Ramatroban (INN) is a thromboxane receptor antagonist.^[1]

It is also a DP₂ receptor antagonist.^[2]

It is indicated for the treatment of coronary artery disease.^[3] It has also been used for the treatment of asthma.^[4]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

1. Sugimoto H, Shichijo M, Iino T, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388.
2. Royer JF, Schratl P, Carrillo JJ, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
3. Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke 21 (12 Suppl): IV149–51. PMID 2260140.
4. Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese) 54 (11): 3045–8. PMID 8950952.

External links

• (Japanese) Baynas